NY-BR-1 (ANKRD30A) Polyclonal

NY-BR-1 (also known as ANKRD30A) is a novel differentiation marker predominantly expressed in normal breast and breast cancer. Except normal testis, no other normal tissue or tumors showed NY-BR-1 expression. Invasive carcinoma of the breast and carcinoma in situ were positive for NY-BR-1, whereas most other tumors and normal tissues are negative, except normal testis. Sweat gland carcinomas, which are related to breast cancer, are also positive in about one-third of the cases. NY-BR-1 is expressed more frequently in estrogen-positive and lymph node-negative primary carcinomas, and more commonly in grade 1 than in grade 2 or grade 3. Some studies show that 49% lymph node metastasis was shown to be positive. These data indicate that NY-BR-1 is a differentiation antigen of the mammary gland that could be useful for diagnosis and/or immunotherapy of breast carcinomas.